| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,090,000 |
| Market
Cap: |
305.28(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.84 - $22.64 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile roGen Pharma is a biopharmaceutical company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co.'s approved product Jelmyto® (mitomycin) for pyelocalyceal solution, and its investigational candidate, UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. In addition, Co.'s immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
20,782 |
29,564 |
33,364 |
41,023 |
| Total Sell Value |
$307,180 |
$445,409 |
$513,847 |
$580,710 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
3 |
5 |
6 |
11 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-03-18 |
4 |
S |
$14.05 |
$168,600 |
D/D |
(12,000) |
139,437 |
|
2% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2024-02-01 |
4/A |
S |
$15.78 |
$78,790 |
D/D |
(4,993) |
23,414 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-02-01 |
4/A |
S |
$15.78 |
$59,790 |
D/D |
(3,789) |
151,437 |
|
- |
|
| Kim Dong |
Chief Financial Officer |
• • – |
2024-01-31 |
4/A |
OE |
$0.00 |
$0 |
D/D |
3,333 |
35,253 |
|
- |
|
| Smith Jason Drew |
General Counsel |
• • – |
2024-01-31 |
4 |
S |
$15.74 |
$78,590 |
D/D |
(4,993) |
23,414 |
|
10% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2024-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
26,742 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-01-31 |
4 |
S |
$15.74 |
$59,639 |
D/D |
(3,789) |
151,437 |
|
10% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,666 |
153,331 |
|
- |
|
| Kim Dong |
Chief Financial Officer |
• • – |
2024-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
26,585 |
|
- |
|
| Smith Jason Drew |
General Counsel |
• • – |
2023-08-31 |
4 |
S |
$18.01 |
$68,438 |
D/D |
(3,800) |
18,407 |
|
19% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2023-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,334 |
22,207 |
|
- |
|
| Cohen Fred E |
Director |
• • – |
2023-07-26 |
4 |
A |
$9.54 |
$661,494 |
I/I |
69,339 |
69,339 |
|
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• • – |
2023-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,333 |
326,691 |
|
- |
|
| Smith Jason Drew |
General Counsel |
• • – |
2023-01-31 |
4 |
S |
$10.12 |
$16,556 |
D/D |
(1,636) |
13,873 |
|
-12% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2023-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
15,100 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2023-01-31 |
4 |
S |
$10.12 |
$19,228 |
D/D |
(1,900) |
148,560 |
|
-12% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2023-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,833 |
149,221 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2023-01-20 |
4 |
OE |
$5.00 |
$613,385 |
D/D |
122,677 |
146,627 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2022-10-31 |
4 |
S |
$11.85 |
$3,057 |
D/D |
(258) |
23,950 |
|
15% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2022-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
500 |
24,208 |
|
- |
|
| Nussbaum Ran |
Director |
• • – |
2022-10-21 |
4/A |
OE |
$5.94 |
$285,114 |
I/I |
47,999 |
1,485,168 |
|
- |
|
| Nussbaum Ran |
Director |
• • – |
2022-10-21 |
4 |
OE |
$5.94 |
$285,114 |
I/I |
47,999 |
1,481,927 |
|
- |
|
| Belldegrun Arie |
Director |
• • – |
2022-09-14 |
4 |
OE |
$5.00 |
$800,000 |
D/D |
160,000 |
408,693 |
|
- |
|
| Belldegrun Arie |
Director |
• • – |
2022-08-31 |
4 |
OE |
$5.00 |
$16,205 |
D/D |
3,241 |
248,693 |
|
- |
|
| Smith Jason Drew |
General Counsel |
• • – |
2022-08-31 |
4 |
S |
$7.21 |
$25,999 |
D/D |
(3,606) |
12,176 |
|
-17% |
|
156 Records found
|
|
Page 1 of 7 |
|
|
0.22 (1.57%) 
